OBJECTIVE: To evaluate the effect of adding bevacizumab to adjuvant @entity1311 and @entity3003 and as maintenance on progression-free survival (PFS) in advanced or recurrent @entity1204 ( @entity1204 ). METHODS: A phase II trial was conducted in @entity1 with measurable disease. @entity1311 (175mg/m(2)/3h), @entity3003 (AUC 5) and bevacizumab (15mg/kg) were administered q 21 days. @entity1 with a complete response after 6-8cycles received maintenance therapy with bevacizumab 15mg/kg q 21 days for 16cycles. Based on GOG 177 which had a 6-month PFS rate of 59%, an increase in 6-month PFS to 72% with the treatment regimen was considered of clinical interest. RESULTS: 15 @entity1 were enrolled on protocol when accrual to the study was discontinued due to the initiation of a national randomized phase II trial. A total of 127 courses (median 8, range 1-20) of @entity3003 , @entity1311 , and bevacizumab combination therapy were administered. One @entity1 suffered a bowel perforation after her first course of therapy and was inevaluable for response. Fourteen of the 15 @entity1 (93%, 95% CI: 82-100) were progression free at 6months. The median follow-up was 36months (7-58+). The median PFS was 18months (CI: 11-25). Five complete responses and 6 partial responses were seen for an overall response rate of 73% (CI: 45-91). The median overall survival was 58months (CI: 48-68). CONCLUSIONS: The bevacizumab, @entity1311 , and @entity3003 regimen is active and tolerable in advanced and recurrent @entity1204 . Its impact awaits results of the recently completed randomized phase II trial.

A phase II trial of @entity1311 , @entity3003 , and bevacizumab in advanced and recurrent @entity1204 ( XXXX ).

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial carcinoma', 'EMCA'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Paclitaxel']
@entity1204 :: (MESH:D016889,Disease) :: ['EMCA']
